Boehringer Ingelheim and Lilly Report Results of Jardiance (empagliflozin) in P-III EMPERIAL Studies for Chronic Heart Failure

 Boehringer Ingelheim and Lilly Report Results of Jardiance (empagliflozin) in P-III EMPERIAL Studies for Chronic Heart Failure

Boehringer Ingelheim and Lilly Report Results of Jardiance (empagliflozin) in P-III EMPERIAL Studies for Chronic Heart Failure

Shots:

  • The two P-III EMPERIAL-preserved & -reduced studies involve assessing the effect of 12wks. treatment of Jardiance (qd, 10mg) vs PBO in 315 & 312 patients with CHF along with HFpEF & HFrEF respectively
  • The two P-III EMPERIAL-reduced & EMPERIAL-preserved studies demonstrated no change in baseline to 12wks. in exercise ability, as measured by the six-minute walk test, no new safety is identified
  • Jardiance (empagliflozin, qd, 20mg) is an oral therapy used to lower the blood sugar level in adults with T2D and cardiovascular diseases and is contraindicated in patients with T1D and diabetic ketoacidosis

Click here ­to­ read full press release/ article | Ref: Lilly | Image: Yahoo Finance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post